SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ICOS Corporation
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DJ who wrote (718)6/15/1999 11:54:00 PM
From: Lel H  Read Replies (1) of 1139
 
Leukarrest wasn't Icos's prime pipeline drug

I would have to disagree with you on this point. LeukArrest is most certainly its lead product at this time, and ICOS obviously put a lot of weight in it since it is/was testing it in four independent indications (shock, MI, stroke, MS). So far, two of four looks like busts, though the stroke indication has moved onto phase III. However, as I think I mentioned in the past, there is a long history of failure in the neuroprotective field, so LeukArrest has an uphill battle for this indication.

Regards,
Lel
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News